Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)

Authors:

Abstract
No abstract available
Funding Information
  • National Cancer Center (P20GM130423)
  • National Institute of General Medical Sciences (P20GM130423)
  • Breast Cancer Research Foundation (BCRF SPEC-2023)
  • Breast Cancer Research Foundation (BCRF SPEC-2024)
  • University of Kansas
  • Hope Foundation
  • National Cancer Institute (U10CA180888)
  • National Cancer Institute (P30 CA168524)
  • National Cancer Institute (U24CA196175)
  • National Cancer Institute (U10CA180819)
  • Children's Mercy Hospital
  • National Institutes of Health

This publication has 31 references indexed in Scilit: